IFNG and neoplasm: In fact, this is supported by recent data from a clinical trial that suggests reverting the T-cell exhaustion in GBM by anti-PD1 immunotherapy leads to a restoration of IFN-γ-producing T cells and improves survival due to T cells targeting the tumor via IFN-γ (41).